Radioactive drug shows promise against advanced cancers

NCT ID NCT03872778

Completed Disease control Sponsor: Advanced Accelerator Applications Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

Addenbroke's hospital

Cambridge, United Kingdom
CHU de Grenoble

La Tronche, France
City of Hope

Duarte, California, 91010, United States
Erasmus MC

Rotterdam, Netherlands
John Hopkins University

Baltimore, Maryland, 21287, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Medical University of Innsbruck

Innsbruck, Austria
Oregon Health & Science University

Portland, Oregon, 97239, United States
Pittsburgh University

Pittsburgh, Pennsylvania, 15213, United States
Stanford University

Stanford, California, 94305, United States
Vall d'Hebron Institute of Oncology

Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.